Amplification of MMP-2 and MMP-9 production by prostate cancer cell lines via activation of protease-activated receptors

Prostate

Volumn 60, Issue 2, 2004, Pages 168-174

  Wilson, Susan R ^a   Gallagher, Sandra ^a   Warpeha, Kate ^a   Hawthorne, Susan J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Matrix metallo proteinases; Metastasis; Prostate cancer; Protease activated receptors

Indexed keywords

ANDROGEN; GELATINASE A; GELATINASE B; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; PROTEINASE ACTIVATED RECEPTOR 3; PROTEINASE ACTIVATED RECEPTOR 4;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME SYNTHESIS; GENE AMPLIFICATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOFLUOROCHEMISTRY; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANDROGENS; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; PROSTATIC NEOPLASMS; RECEPTOR, PAR-1; RECEPTOR, PAR-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 2942530298     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20047     Document Type: Article

References (45)

1. Curran S, Murray GI. Matrix metalloproteinases: Molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 2000;36:1621-1630.
2. Stearns M, Stearns ME. Evidence for increased activated metalloproteinase 2 (MMP-2a) expression associated with human prostate cancer progression. Oncology Res 1996;8(2):69-75.
3. Lokeshwar BL. MMP inhibition in prostate cancer. Ann NY Acad Sci 1999;878:271-289 (review).
4. Hollenberg MD, Compton SJ. International Union of Pharmacology. XXVIII. Proteinase-activated receptors. Pharmacol Rev 2002;54(2):203-217 (review).
5. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991;64(6):1057-1068.
6. Nystedt SK, Emilsson C, Wahlestedt X, Sundelin J. Molecular cloning of a potential protease activated receptor. Proc Natl Acad Sci USA 1994;91:9208-9212.
7. Ishihara H, Connolly AJ, Zeng D, Kahn ML, Zheng YW, Timmons C, Tram T, Coughlin SR. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 1997; 386(6624):502-506.
8. Xu WF, Andersen H, Whitmore TE, Presnell SR, Yee DP, Ching A, et al. Cloning and characterisation of human protease-activated receptor 4. Proc Natl Acad Sci USA 1998;95(12): 6642-6646.
9. Smith R, Jenkins A, Lourbakos A, Thompsin P, Ramakrishnan V, Tomlinson J, et al. Evidence for the activation of PAR-2 by the sperm prostease, acrosin: Expression of the receptor on oocytes. FEBS Lett 2000;484(3):285-290.
10. Schmidlin F, Bunnett N. Protease-activated receptors: How proteases signal to cells. Curr Opin Pharmacol 2001;1:575-582.
11. Vliagoftis H, Schwingshackl A, Milne CD, Duszyk M, Hollenberg MD, Wallace JL, et al. Proteinase-activated receptor-2-mediated matrix metalloproteinase-9 release from airway epithelial cells. J Allergy Clin Immunol 2000;106(3):537-545.
12. Duhamel-Clerin E, Orvain C, Lanza F, Cazenave J-P, Klein-Soyer C. Thrombin receptor-mediated increase of two matrix metalloproteinases, MMP-1 and MMP-3, in human endothelial cells. Atherioscler Thromb Vasc Biol 1997;17(10):1931-1938.
13. Nierodzik ML, Chen K, Takeshita K, Li JJ, Huang YQ, Feng XS, et al. Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis. Blood 1998;92(10):3694- 3700.
14. Even-Ram S, Uziely B, Cohen P, Grisaru-Graanovsky S, Maoz M, Ginzburg Y, et al. Thrombin receptor overexpression in malignant and physiological invasion process. Nat Med 1998;4(8): 909-914.
15. Huang YQ, Li JJ, Hu L, Lee M, Karpatkin S. Thrombin induces increased expression and secretion of angiopoietin-2 from human umbilical vein endothelial cells. Blood 2002;99(5):1646-1650.
16. Liu Y, Gilcrease MZ, Henderson Y, Yuan ZH, Clayman GL, Chen Z. Expression of protease-activated receptor 1 in oral squamous cell carcinoma. Cancer Lett 2001;169:173-180.
17. Hirahara F, Miyagi Y, Miyagi E, Yasumitsu H, Koshikawa N, Nagashima Y, et al. Trypsinogen expression in human ovarian carcinomas. Int J Cancer 1995;63:176-181.
18. Koivunen E, Huhtala M-L, Stenman U-H. Human ovarian tumor-associated trypsin. J Biochem Soc 1989;264(24):14095-14099.
19. Terada T, Okada Y, Nakanuma Y. Expression of matrix proteinases during human intrahepatic bile duct development. Am J Pathol 1995;147(5):1207-1213.
20. Sorsa T, Salo T, Koivunen E, Tyynela J, Konttinen YT, Bergmann U, et al. Activation of type IV procollagenases by human tumor-associated trypsin-2. J Biol Chem 1997;272(34):21067-21074.
21. Miyata S, Miyagi Y, Koshikawa N, Nagashima Y, Kato Y, Yasumitsu H, et al. Stimulation of cellular growth and adhesion to fibronectin and vitronectin in culture and tumorigenicity in nude mice by overexpression of trypsinogen in human gastric cancer cells. Clin Exp Metastasis 1998;16:613-622.
22. Nyberg P, Moilanen M, Paju A, Sarin A, Stenman U-H, Sorsa T, et al. MMP-9 activation by tumor typsin-2 enhances in vivo invasion of human tongue carcinoma cells. J Dent Res 2002; 81(12):831-835.
23. Stenman U-H. Tumour-associated trypsin inhibitor and tumour-associated trypsin. Scand J Clin Lab Invest Suppl 1990; 50(Suppl 201):93-101.
24. Alm A-K, Gagnemo-Persson R, Sorsa T, Sundelin J. Extra-pancreatic trypsin-2 cleaves proteinase-activated receptor-2. Biochem Biophys Res Commun 2000;275:77-83.
25. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics. CA Cancer J Clin 2001;51(1):15-36.
26. Foda HD, Zucker S. Matrix metalloproteinases in cancer invasion, metastatsis, and angiogenesis. Drug Discov Today 2001; 6(9):478-482.
27. Blasi F, Stoppelli MP. Proteases and cancer invasion: From belief to certainty AACR meeting on proteases and protease inhibitors in cancer, Nyborg, Denmark, 14-18 June 1998. Biochim Biophys Acta 1998;1423:R35-R44.
28. Bodey B, Bodey B, Groger AM, Siegel SE, Kaiser HE. Invasion and metastasis: The expression and significance of matrix metalloproteinases in carcinomas of the lung. In Vivo 2001; 15(2):175-180.
29. Bodey B, Bodey B, Siegel SE, Kaiser HE. Matrix metalloproteinase expression in malignant melanomas: Tumor-extracellular matrix interactions in invasion and metastasis. In Vivo 2001; 15(1):57-64.
30. Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 1999;189:300-308.
31. Bello-DeOcampo D, Kleinman HK, Webber MM. The role of α6β1 integrin and EGF in normal and malignant acinar morphogenesis of human prostatic epithelial cells. Mutat Rev 2001;480-481:209-217.
32. Crawford HC, Matrisian LM. Mechanisms controlling the transcription of matrix metalloproteinase genes in normal and neoplastic cells. Enzyme Protein 1996;49:20-37.
33. Quax PHA, de Bart ACW, Schalden JA, Verheijen JH. Plasminogen activator and matrix metalloproteinase production and extracellular matrix degradation by rat prostate cancer cells in vitro: Correlation with metastatic behavior in vivo. Prostate 1997;32:196-204.
34. Webber MM, Waghray A, Rhim JS, Deocampo ND. Urokinase and gelatinises in the proteolytic cascade in human prostate cancer invasion: Implication in cancer prevention. Proc Am Assoc Cancer Res 1995;36:643.
35. Stearns ME, Wang M. Type IV collagenase (Mr 72,000) expression in human prostate: Benign and malignant tissue. Cancer Res 1993;53:878-883.
36. Schmalfeldt B, Prechtel D, Harting K, Spathe K, Rutke S, Konik E. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res 2001;7:2396-2404.
37. Kallakury BVS, Karikehalli S, Haholu A, Sheehan CE, Azumi N, Ross JS. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 2001;7:3113-3119.
38. Morris MJ, Scher HI. Novel therapies for the treatment of prostate cancer: Current clinical trials and development strategies. Surg Oncol 2002;11:13-23.
39. Wojtukiewicz MZ, Tang KG, Ciarelli JJ, Nelson KK, Walz DA, Diglio CA. Thrombin increases the metastatic potential of tumour cells. Int J Cancer 1993;54(5):793-806.
40. Nierodizik ML, Kajumo F, Karpatkin S. Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo. Cancer Res 1992;52:3267-3272.
41. Tsopanoglou NE, Maragoudakis ME. On the mechanism of thrombin-induced angiogenesis. Potentiation of vascular enclothelial growth factor activity on endothelial cells by upregulation of its receptors. J Biol Chem 1999;274(34):23969-23976.
42. Koivunen E, Saksela O, Itkonen O, Osman S, Huhtala M-L, Stenman U-H. Human colon carcinoma, fibrosarcoma, and leukaemia cell lines produce tumor-associated trypsinogen. Int J Cancer 1991;47:592-596.
43. Ohta T, Terada T, Nagakawa T, Tajima H, Itoh H, Fonseca L, et al. Pancreatic trypsinogen and cathepsin B in human pancreatic carcinomas and associated metastatic lesions. Br J Cancer 1994; 69:152-156.
44. Huang YQ, Li JJ, Karpatkin S. Thrombin inhibits tumor cell growth in association with upregulation of p21(waf/cip1) and caspases via a p53-independent, STAT-1-dependent pathway. J Biol Chem 2000;375(9):6462-6468.
45. Greenberg DL, Mize GJ, Takayama TK. Protease-activated receptor mediated Rho A signalling and cytoskeletal reorganization in LNCaP cells. Biochemistry 2003;42(3):702-709.